Cíntia Ferreira-Pêgo1, Nancy Babio1, Maira Bes-Rastrollo2, Dolores Corella3, Ramon Estruch4, Emilio Ros5, Montserrat Fitó6, Lluís Serra-Majem7, Fernando Arós8, Miguel Fiol9, José Manuel Santos-Lozano10, Carlos Muñoz-Bravo11, Xavier Pintó12, Miguel Ruiz-Canela2, Jordi Salas-Salvadó13. 1. Human Nutrition Unit, Hospital Universitari de Sant Joan de Reus, Faculty of Medicine and Health Sciences, IISPV (Institut d'Investigació Sanitària Pere Virgili), Biochemistry Biotechnology Department, Universitat Rovira i Virgili, Reus, Spain; CIBEROBN (Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición) and. 2. CIBEROBN (Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición) and Department of Preventive Medicine and Public Health, School of Medicine, University of Navarra, Pamplona, Spain; IDISNA (Instituto de Investigación Sanitaria de Navarra), Pamplona, Spain. 3. CIBEROBN (Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición) and Department of Preventive Medicine, University of Valencia, Valencia, Spain; 4. CIBEROBN (Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición) and Prevention with Mediterranean Diet Research Network (PREDIMED), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Internal Medicine and. 5. CIBEROBN (Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición) and Lipid Clinic, Endocrinology, and Nutrition Service, Institut d'Investigacions Biomèdiques August Pi Sunyer, Hospital Clínic, University of Barcelona, Barcelona, Spain; 6. CIBEROBN (Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición) and Cardiovascular Risk and Nutrition Research Group, Medical Research Institute of Del Mar Hospital, Barcelona, Spain; 7. CIBEROBN (Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición) and Prevention with Mediterranean Diet Research Network (PREDIMED), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain; 8. CIBEROBN (Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición) and Prevention with Mediterranean Diet Research Network (PREDIMED), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Cardiology, University Hospital Araba, Vitoria, Spain; 9. CIBEROBN (Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición) and Palma Institute of Health Research, Hospital Son Espases, Palma de Mallorca, Spain; 10. CIBEROBN (Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición) and Department of Family Medicine, Distrito Sanitario Atención Primaria Sevilla, Centro de Salud San Pablo, Seville, Spain; 11. Department of Public Health and Psychiatry, University of Malaga, Malaga, Spain; 12. Department of Internal Medicine and Lipids and Vascular Risk Unit, Internal Medicine Service, University Hospital of Bellvitge, Barcelona, Spain; and. 13. Human Nutrition Unit, Hospital Universitari de Sant Joan de Reus, Faculty of Medicine and Health Sciences, IISPV (Institut d'Investigació Sanitària Pere Virgili), Biochemistry Biotechnology Department, Universitat Rovira i Virgili, Reus, Spain; CIBEROBN (Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición) and Prevention with Mediterranean Diet Research Network (PREDIMED), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; jordi.salas@urv.cat.
Abstract
BACKGROUND: The relation between the consumption of sweetened beverages and metabolic syndrome (MetS) is controversial. OBJECTIVE: This analysis evaluated the associations between intakes of sugar-sweetened beverages (SSBs), artificially sweetened beverages, and natural and bottled fruit juices and the incidence of MetS in elderly individuals at high risk of cardiovascular disease (CVD) and without MetS at baseline. METHODS: We prospectively examined 1868 participants free of MetS at baseline from the PREDIMED (PREvención con DIeta MEDiterránea) study. MetS was defined by using the updated harmonized criteria of the International Diabetes Federation, the American Heart Association, and National Heart, Lung, and Blood Institute. Energy and nutrient intakes were evaluated at baseline and then yearly by using a validated 137-item food-frequency questionnaire. Multivariable-adjusted HRs for MetS and its components were estimated from mean intakes during follow-up. We compared the 2 highest consumption categories (1-5 and >5 servings/wk) with the lowest category (<1 serving/wk). RESULTS: A total of 930 incident cases of MetS were documented during a median follow-up of 3.24 y. When we compared consumption of >5 servings/wk with consumption of <1 serving/wk, multivariable HRs (95% CIs) for MetS incidence were 1.43 (1.00, 2.15), 1.74 (1.26, 2.41), 1.30 (1.00, 1.69), and 1.14 (1.04, 1.65) for SSBs, artificially sweetened beverages, natural fruit juices, and bottled fruit juices, respectively. CONCLUSIONS: The occasional consumption of SSBs and artificially sweetened beverages (1-5 servings/wk) was not associated with the incidence of MetS in middle-aged and elderly individuals at high risk of CVD. The consumption of >5 servings/wk of all of the types of beverages analyzed was associated with an increased risk of MetS and some of its components. However, for SSBs and bottled fruit juices these associations must be interpreted with caution because of the low frequency of consumption in this population. This trial was registered at clinicaltrials.gov as ISRCTN35739639.
BACKGROUND: The relation between the consumption of sweetened beverages and metabolic syndrome (MetS) is controversial. OBJECTIVE: This analysis evaluated the associations between intakes of sugar-sweetened beverages (SSBs), artificially sweetened beverages, and natural and bottled fruit juices and the incidence of MetS in elderly individuals at high risk of cardiovascular disease (CVD) and without MetS at baseline. METHODS: We prospectively examined 1868 participants free of MetS at baseline from the PREDIMED (PREvención con DIeta MEDiterránea) study. MetS was defined by using the updated harmonized criteria of the International Diabetes Federation, the American Heart Association, and National Heart, Lung, and Blood Institute. Energy and nutrient intakes were evaluated at baseline and then yearly by using a validated 137-item food-frequency questionnaire. Multivariable-adjusted HRs for MetS and its components were estimated from mean intakes during follow-up. We compared the 2 highest consumption categories (1-5 and >5 servings/wk) with the lowest category (<1 serving/wk). RESULTS: A total of 930 incident cases of MetS were documented during a median follow-up of 3.24 y. When we compared consumption of >5 servings/wk with consumption of <1 serving/wk, multivariable HRs (95% CIs) for MetS incidence were 1.43 (1.00, 2.15), 1.74 (1.26, 2.41), 1.30 (1.00, 1.69), and 1.14 (1.04, 1.65) for SSBs, artificially sweetened beverages, natural fruit juices, and bottled fruit juices, respectively. CONCLUSIONS: The occasional consumption of SSBs and artificially sweetened beverages (1-5 servings/wk) was not associated with the incidence of MetS in middle-aged and elderly individuals at high risk of CVD. The consumption of >5 servings/wk of all of the types of beverages analyzed was associated with an increased risk of MetS and some of its components. However, for SSBs and bottled fruit juices these associations must be interpreted with caution because of the low frequency of consumption in this population. This trial was registered at clinicaltrials.gov as ISRCTN35739639.
Authors: J H Siqueira; T S Silva Pereira; A D Moreira; M F H S Diniz; G Velasquez-Melendez; M J M Fonseca; S M Barreto; I M Benseñor; J G Mill; M C B Molina Journal: J Endocrinol Invest Date: 2022-08-13 Impact factor: 5.467
Authors: Michele Drehmer; Andrew O Odegaard; Maria Inês Schmidt; Bruce B Duncan; Letícia de Oliveira Cardoso; Sheila M Alvim Matos; Maria Del Carmen B Molina; Sandhi M Barreto; Mark A Pereira Journal: Diabetol Metab Syndr Date: 2017-02-13 Impact factor: 3.320
Authors: Zhila Semnani-Azad; Tauseef A Khan; Sonia Blanco Mejia; Russell J de Souza; Lawrence A Leiter; Cyril W C Kendall; Anthony J Hanley; John L Sievenpiper Journal: JAMA Netw Open Date: 2020-07-01
Authors: Danielle E Haslam; Gina M Peloso; Mark A Herman; Josée Dupuis; Alice H Lichtenstein; Caren E Smith; Nicola M McKeown Journal: J Am Heart Assoc Date: 2020-02-26 Impact factor: 5.501